What drugs does PERRIGO R AND D make?

PERRIGO R AND D has 26 FDA-approved drugs including NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.

What therapeutic areas does PERRIGO R AND D focus on?

PERRIGO R AND D focuses primarily on Gastroenterology and Infectious Disease and 1 other therapeutic areas.

← Back

Data updated: May 24, 2026

PERRIGO R AND D

Generics

Gastroenterology Infectious Disease Cardiovascular

PERRIGO R AND D is a generic drug manufacturer focused on Gastroenterology, Infectious Disease, Cardiovascular.

2005

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

Immunology

Approved 2018

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

Pain

Approved 2014

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

Respiratory

Approved 2015

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Gastroenterology 50%

3 drugs

Infectious Disease 33%

2 drugs

Cardiovascular 17%

1 drugs